Pfizer’s CEO has announced that pending positive results from ongoing clinical trials of their experimental COVID-19 vaccine, the company will apply for Emergency Use Authorisation (EUA) by late November. Once the minimum safety data is obtained, the manufacturer will seek EUA in the United States. The U. S. Food and Drug Administration (FDA), the U.S. regulatory body for medication, requires two months of safety data at minimum. Further information on the FDA’s EUA guidance for COVID-19 vaccines is available here. Information regarding the efficacy of the vaccine is expected by the end of October.